# Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma

> **NCT05622136** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Instituto do Cancer do Estado de São Paulo** · enrollment: 28 (estimated)

## Conditions studied

- Liver Cancer
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Regorafenib Oral Product

## Key facts

- **NCT ID:** NCT05622136
- **Lead sponsor:** Instituto do Cancer do Estado de São Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-10
- **Primary completion:** 2026-11-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05622136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05622136, "Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05622136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*